Agenda
3:00 PM - 3:30 PM Registration and Networking
3:30 PM - 5:00 PM Industry Panel
5:00 PM - 6:30 PM Networking Reception
Overview
Big Pharma Corporate Venture Arm Flexes in Life Science
The significant costs, extended timelines, and regulatory hurdles facing emerging life science companies in today's economy make it increasingly difficult for VCs to make a sizable return on their investment. Can the same be said for corporate investors, or do they have different objectives? What is driving their investment strategy? Is it strategic alignment, an attempt at harnessing innovation, or simply good business? Join us at our next industry panel for an interactive discussion on why and how corporate players are getting in the game and hitting it big! Could this be the changing of the guard in life sciences? Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception.
CONFIRMED PANELISTS
Tiba Aynechi, Principal in Novo Ventures, Novo A/S
Nicole Walker, Director, Abbott Biotech Ventures
Simeon George, Partner, SROne
Juan Harrison, Vice President, Takeda Research Investment
Lead Facilitator: Joseph Perkins, Corporate Senior Associate, Orrick, Herrington & Sutcliffe LLP
Cost & Registration
- Regular Price: $50
- Partners' Network: $40
- Meet with Alumni: $30
- Student: $20
Venue
Orrick, Herrington & Sutcliffe LLP
1000 Marsh Road
Building 1100
Menlo Park, CA 94025-1015
Speakers Bios
Tiba Aynechi, Principal in Novo Ventures,
Novo A/S
Tiba Aynechi joined Novo A/S in 2010 working out of the San Francisco, California office. She has more than 10 years of combined research and banking experience in life sciences that spans various therapeutic areas and technology platforms. Prior to joining Novo A/S, Tiba was a Director with Burrill& Company where she has completed regional and cross-border M&A;, licensing, and financing transactions for biotech and large pharmaceutical companies.
Tiba received her PhD from the Graduate Group in Biophysics at the University of California, San Francisco where her research involved developing computational methods for drug discovery. She has an undergraduate degree in physics from the University of California, Irvine. Tiba is also a published author of scientific articles and book chapters in the area of rational drug design.
Nicole Walker, Director, Abbott Bio Ventures
Nicole joined Abbott in 2005 with more than 10 years of operational and investment experience within the healthcare industry. As a Director for Abbott Biotech Ventures, Nicole is responsible for the evaluation and execution of equity investments in emerging pharma and biotech companies of strategic interest to Abbott. Prior to joining ABV, Nicole spent four years in Global Strategic Marketing with Abbott�s Diabetes Care Division where she managed the strategic planning, market development, and product portfolio initiatives for multiple brands for both discrete and continuous blood glucose monitoring. In addition to her Abbott experience, Nicole spent three years as a Principal with ONSET Ventures where she specialized in seed and early-stage medical investments. Nicole joined ONSET in 2002, after spending more than 8 years with Guidant Corporation where she held a variety of roles within operations, product design & development, engineering management, and lastly marketing, as the Sr. Marketing Manager for Asia, based in Hong Kong, where she was responsible for managing the market development strategies for the implantable and surgical product lines. Nicole earned her MBA from the J.L. Kellogg School of Management and her MEM (Masters of Engineering Management) from the McCormick School of Engineering at Northwestern University. Nicole also holds a B.S. in Mechanical Engineering from Stanford University.
Simeon J. George, Partner, SR One
Tiba Aynechi joined Novo A/S in 2010 working out of the San Francisco, California office. She has more than 10 years of combined research and banking experience in life sciences that spans various therapeutic areas and technology platforms. Prior to joining Novo A/S, Tiba was a Director with Burrill& Company where she has completed regional and cross-border M&A;, licensing, and financing transactions for biotech and large pharmaceutical companies.
Tiba received her PhD from the Graduate Group in Biophysics at the University of California, San Francisco where her research involved developing computational methods for drug discovery. She has an undergraduate degree in physics from the University of California, Irvine. Tiba is also a published author of scientific articles and book chapters in the area of rational drug design.
Juan Harrison, Vice President, Takeda Research Investment
Mr. Harrison joined TRI as Vice President in January 2008. He brings more than 21 years of biopharmaceutical R&D;, product licensing, business development and strategy experience. Most recently, Mr. Harrison was a partner with ProPharma Partners International, where he specialized in developing and implementing business and licensing strategy for emerging and established biopharmaceutical companies. Prior to this, he held senior business development positions at XenoPort Inc., PowderJect Inc., Connetics Corporation and Alza Corporation. In addition, Mr. Harrison held product development management and research positions at Alza, where he began his career in 1985. Mr. Harrison received his Bachelor of Sciences in Combined Sciences from Santa Clara University in California, USA.
.
Joseph Perkins, Corporate Senior Associate, Orrick, Herrington & Sutcliffe LLP
Joseph Z. Perkins, a corporate associate in Orrick's Silicon Valley office, is a member of the Emerging Companies Group, which advises emerging companies and venture capital firms. Mr. Perkins's practice focuses on providing private venture financing and merger and acquisition services to Internet, high tech, and clean technology companies.
